Testosterone
- Generic Name
- Testosterone
- Brand Names
- Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O2
- CAS Number
- 58-22-0
- Unique Ingredient Identifier
- 3XMK78S47O
- Background
Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.
Testosterone was isolated from samples and also synthesized in 1935.
- Indication
Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.
- Associated Conditions
- Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
- Associated Therapies
- -
Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Lars Møller Pedersen
- Target Recruit Count
- 7
- Registration Number
- NCT04492553
- Locations
- 🇩🇰
Herlev University Hospital, Herlev, Denmark
🇩🇰Copenhagen University Hospital, Copenhagen, Denmark
🇩🇰Zealand University Hospital, Roskilde, Denmark
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 676
- Registration Number
- NCT04456296
- Locations
- 🇺🇸
Endo Clinical Trial Site #22, Tucson, Arizona, United States
🇺🇸Endo Clinical Trial Site #3, Oviedo, Florida, United States
🇺🇸Endo Clinical Trial Site #27, Glen Burnie, Maryland, United States
Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Laboratorios Andromaco S.A.
- Target Recruit Count
- 46
- Registration Number
- NCT03967964
- Locations
- 🇨🇱
Instituto de Investigación Materno Infantil (IDIMI) - Maternidad Hospital San Borja (HCSBA), Santiago, Chile
Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 30
- Registration Number
- NCT03619330
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 26
- Registration Number
- NCT03238092
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 60
- Registration Number
- NCT03203681
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Marius Pharmaceuticals
- Target Recruit Count
- 314
- Registration Number
- NCT03198728
- Locations
- 🇺🇸
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Primary Care Research Group, Atlanta, Georgia, United States
🇺🇸National Clinical Research, Inc., Richmond, Virginia, United States
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT03118479
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Subcutaneous vs. Intramuscular Testosterone
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Men's Health Boston
- Target Recruit Count
- 4
- Registration Number
- NCT03091348
- Locations
- 🇺🇸
Men's Health Boston, Chestnut Hill, Massachusetts, United States
Study of Testosterone vs Placebo in Testicular Cancer Survivors
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Mikkel Bandak
- Target Recruit Count
- 69
- Registration Number
- NCT02991209
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.